Estrogen receptor alpha (membrane-associated) (mERα)

Estrogen receptor alpha (ERα) is a ligand-activated transcription factor encoded by the ESR1 gene, primarily known for its role in the nucleus. However, a distinct pool of ERα is localized to the plasma membrane, where it is referred to as membrane-associated estrogen receptor alpha (mERα). This localization is typically achieved through post-translational palmitoylation at the Cys447 residue, which facilitates its association with caveolin-1 and lipid rafts (Source: UniProt P03372; PubMed: 23536014). Unlike the slower genomic effects of nuclear ERα, mERα mediates rapid, non-genomic signaling pathways, such as the activation of MAPK/ERK, PI3K/Akt, and calcium signaling, within minutes of estrogen binding (Source: NIH/NCBI PMC3652620). These rapid responses are crucial for physiological processes like vasodilation and neuroprotection, but they also contribute to the proliferation and survival of breast cancer cells. In the context of oncology, mERα is a significant factor in resistance to endocrine therapies, as it can maintain cellular signaling even when nuclear activity is suppressed (Source: PubMed: 21148111). Most clinical ER-targeted therapies, including Selective Estrogen Receptor Modulators (SERMs) like Tamoxifen and Selective Estrogen Receptor Degraders (SERDs) like Fulvestrant, interact with both the nuclear and membrane-associated pools of the receptor (Source: PubChem CID 5284543).

Other names

Membrane-bound estrogen receptor alphamER-alphaPalmitoylated estrogen receptor alphaESR1 (membrane-localized)Extranuclear estrogen receptor alpha

Ligand-induced activation of rapid non-genomic signaling cascades (e.g., MAPK, PI3K) via membrane-localized receptors and competitive inhibition or degradation of the receptor to block estrogenic signaling.